Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2024-01-08 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2023. It is addressed to stock exchanges and is a compliance certificate from the Registrar and Share Transfer Agent. The document is short (1958 characters) and does not contain financial statements or substantive financial data. It is a regulatory compliance filing rather than a financial report or announcement of voting results, management changes, or capital updates. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate filing.
2024-01-08 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter from Concord Biotech Limited addressed to stock exchanges regarding the closure of the trading window pursuant to SEBI regulations ahead of the announcement of unaudited financial results for the quarter and nine months ended December 31, 2023. It does not contain any financial data or the results themselves but informs about the trading restrictions before the results are declared. The document length is short (2632 characters) and it is an announcement related to the timing of financial results, not the results or report itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a compliance-related announcement and does not contain substantive financial information or the report itself.
2023-12-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter dated December 14, 2023, from Concord Biotech Limited addressed to stock exchanges (NSE and BSE). It informs about the schedule of analyst and institutional investor meetings. The letter explicitly states that discussions will be based on publicly available information and no unpublished price sensitive information will be discussed. It is submitted pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which relates to disclosure of events or information. The document does not contain any financial data, results, or detailed reports but is an announcement of upcoming investor meetings. Therefore, it is an update related to investor relations but not a financial report or earnings release. Given the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the schedule of analyst and institutional investor meetings. It explicitly states that the discussions will be based on publicly available information and no unpublished price sensitive information will be discussed. The document is an intimation under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of events or information. The document is short (2331 characters) and serves as a notification of upcoming investor meetings rather than a report or detailed presentation. It does not contain financial data, management discussion, or any report content. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q2 and H1 FY24 earnings conference call of Concord Biotech Limited held on November 09, 2023. It includes management commentary, financial performance highlights, and a Q&A session. The text explicitly mentions it is a transcript of the earnings call, with detailed discussion of quarterly and half-year financial results, growth drivers, and outlook. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters long, contains substantive financial data and management discussion, and is not merely an announcement or a brief summary. Therefore, the correct classification is CT with high confidence.
2023-11-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the earnings call recording for the quarter and half year ended September 30, 2023. It references the earnings call and provides a link to the audio recording but does not contain the transcript or detailed financial results itself. The document length is short (2181 characters) and serves as an announcement of the earnings call recording availability rather than the earnings release or call transcript itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the earnings call recording, not the earnings release or transcript.
2023-11-09 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.